Research ArticleVaccines

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

See allHide authors and affiliations

Science Translational Medicine  17 Jul 2019:
Vol. 11, Issue 501, eaaw2603
DOI: 10.1126/scitranslmed.aaw2603

Article Information

vol. 11 no. 501

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication December 3, 2018
  • Resubmitted March 14, 2019
  • Accepted for publication June 13, 2019
  • .

Author Information

  1. Emily E. Marshall1,*,,
  2. Daniel Malouli1,*,
  3. Scott G. Hansen1,*,
  4. Roxanne M. Gilbride1,
  5. Colette M. Hughes1,
  6. Abigail B. Ventura1,
  7. Emily Ainslie1,
  8. Andrea N. Selseth1,
  9. Julia C. Ford1,
  10. David Burke1,
  11. Craig N. Kreklywich1,
  12. Jennie Womack1,
  13. Alfred W. Legasse1,
  14. Michael K. Axthelm1,
  15. Christoph Kahl1,,
  16. Daniel Streblow1,
  17. Paul T. Edlefsen2,
  18. Louis J. Picker1,§ and
  19. Klaus Früh1,§
  1. 1Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  2. 2Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  1. §Corresponding author. Email: pickerl{at}ohsu.edu (L.J.P.); fruehk{at}ohsu.edu (K.F.)
  • * These authors contributed equally to this work.

  • Present address: Vir Biotechnology, 4640 SW Macadam Avenue, Portland, OR 97239, USA.

  • Present address: Atara Biotherapeutics, 611 Gateway Boulevard Suite 900, South San Francisco, CA 94080, USA.

Altmetric

Article usage

Article usage: July 2019 to November 2019

AbstractFullPdf
Jul 201934881554304
Aug 201975711377
Sep 20191205039
Oct 20191455449
Nov 2019311310